10 results on '"Giebl, Andreas"'
Search Results
2. Viscoelastometry for detecting oral anticoagulants
- Author
-
Groene, Philipp, Wagner, Daniela, Kammerer, Tobias, Kellert, Lars, Giebl, Andreas, Massberg, Steffen, and Schäfer, Simon Thomas
- Published
- 2021
- Full Text
- View/download PDF
3. Additional file 1 of Viscoelastometry for detecting oral anticoagulants
- Author
-
Groene, Philipp, Wagner, Daniela, Kammerer, Tobias, Kellert, Lars, Giebl, Andreas, Massberg, Steffen, and Schäfer, Simon Thomas
- Abstract
Additional file 1 Supplemental Table 1A: Viscoelastometric and standard laboratory test results from the control group and the anticoagulant groups. Data are presented as median (interquartile range); p-values are for comparison with the control group. Supplemental Table 1B: Viscoelastometric CT results from the control group and the anticoagulant groups, with pooling of the FXa inhibitors. Data are presented as median (interquartile range); p-values are for comparison with the control group.
- Published
- 2021
- Full Text
- View/download PDF
4. Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry
- Author
-
Kammerer, Tobias, primary, Groene, Philipp, additional, Sappel, Sophia R., additional, Peterss, Sven, additional, Sa, Paula A., additional, Saller, Thomas, additional, Giebl, Andreas, additional, Scheiermann, Patrick, additional, Hagl, Christian, additional, and Schäfer, Simon Thomas, additional
- Published
- 2020
- Full Text
- View/download PDF
5. External quality assessment for the quality assurance of haemostaseological global tests/POCT
- Author
-
Kragh, Thorsten, Giebl, Andreas, Müller, Michaela, Kutsch, Mareen, and Spannagl, Michael
- Subjects
ddc: 610 ,Ringversuche ,whole blood ,hemostasis ,Gerinnung ,610 Medical sciences ,Medicine ,external quality assessment ,POCT ,Vollblut - Abstract
External quality assessment contributes essentially to quality assurance in medical diagnostics. Especially POCT of hemostasis diagnostics make this a particular challenging task for participants and the EQA organization, as the required whole blood samples are particularly sensitive to transport and waiting times. In addition, device manufacturers provide a variety of measuring methods that are not equally suitable for the use of the EQA sample. Over the past few years, conditions for the EQA of hemostasis POCT in whole blood have been adjusted and improved. Meanwhile the EQA show an acceptable passing rate, even though in general it remains a great challenge to adapt the EQA samples to the whole blood or plasma sample of the daily routine., Ringversuche leisten für die Qualitätssicherung in der medizinischen Diagnostik einen essentiellen Beitrag. Speziell POCT der Gerinnungsdiagnostik stellen hierbei besondere Herausforderungen an Teilnehmer und Ringversuchsorganisation, da die benötigten Vollblutproben besonders sensibel auf Transport und Wartezeiten reagieren. Zusätzlich werden von den Geräteherstellern verschiedenste Messverfahren verwendet, die sich unterschiedlich gut für den Einsatz der Ringversuchsprobe eignen. Über die vergangenen Jahre wurden Bedingungen für die Ringversuche der Gerinnungs-POCT im Vollblut angepasst und verbessert. Die Ringversuche zeigen inzwischen akzeptable Bestehensquoten (75–100%), auch wenn es grundsätzlich eine große Herausforderung bleibt, Ringversuchsproben an die Vollblut- oder Plasmaprobe des Alltags anzupassen., GMS Zeitschrift zur Förderung der Qualitätssicherung in medizinischen Laboratorien; 9:Doc02
- Published
- 2018
- Full Text
- View/download PDF
6. Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry.
- Author
-
Kammerer, Tobias, Groene, Philipp, Sappel, Sophia R., Peterss, Sven, Sa, Paula A., Saller, Thomas, Giebl, Andreas, Scheiermann, Patrick, Hagl, Christian, and Schäfer, Simon Thomas
- Abstract
Introduction: Tranexamic acid (TXA) is the standard medication to prevent or treat hyperfibrinolysis. However, prolonged inhibition of lysis (so-called "fibrinolytic shutdown") correlates with increased mortality. A new viscoelastometric test enables bedside quantification of the antifibrinolytic activity of TXA using tissue plasminogen activator (TPA). Materials and Methods: Twenty-five cardiac surgery patients were included in this prospective observational study. In vivo, the viscoelastometric TPA test was used to determine lysis time (LT) and maximum lysis (ML) over 96 h after TXA bolus. Additionally, plasma concentrations of TXA and plasminogen activator inhibitor 1 (PAI-1) were measured. Moreover, dose effect curves from the blood of healthy volunteers were performed in vitro. Data are presented as median (25–75th percentile). Results: In vivo TXA plasma concentration correlated with LT (r = 0.55; p < 0.0001) and ML (r = 0.62; p < 0.0001) at all time points. Lysis was inhibited up to 96 h (LT
TPA-test : baseline: 398 s [229–421 s] vs. at 96 h: 886 s [626–2,175 s]; p = 0.0013). After 24 h, some patients (n = 8) had normalized lysis, but others (n = 17) had strong lysis inhibition (ML <30%; p < 0.001). The high- and low-lysis groups differed regarding kidney function (cystatin C: 1.64 [1.42–2.02] vs. 1.28 [1.01–1.52] mg/L; p = 0.002) in a post hoc analysis. Of note, TXA plasma concentration after 24 h was significantly higher in patients with impaired renal function (9.70 [2.89–13.45] vs.1.41 [1.30–2.34] µg/mL; p < 0.0001). In vitro, TXA concentrations of 10 µg/mL effectively inhibited fibrinolysis in all blood samples. Conclusions: Determination of antifibrinolytic activity using the TPA test is feasible, and individual fibrinolytic capacity, e.g., in critically ill patients, can potentially be measured. This is of interest since TXA-induced lysis inhibition varies depending on kidney function. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. Thrombelastometry - internal and external quality control
- Author
-
Kragh, Thorsten, Giebl, Andreas, Dick, Andrea, Kutsch, Mareen, and Spannagl, Michael
- Subjects
ROTEM ,ExTEM ,ddc: 610 ,EQAS ,Ringversuche ,externe Qualitätskontrolle ,InTEM ,610 Medical sciences ,Medicine ,external quality control - Abstract
Patient near diagnostics ensure the monitoring of the individual hemostatic capacity of surgery and intensive care patients. Therefor thrombelastometry provideds a series of standard measurements. The challenge for such a bedside diagnostic method is that it can be performed by “laboratory-unexpierenced” staff, and special attention has to be paid to result validation. External quality controls with External Quality Assessment Schemes (EQAS) provide an appropriate instrument, which was established for the thrombelastometry. The increasing number of participants and good pass rates show the relevance of this topic. Here we present a summary of the results and experiences of four consecutive EQAS. With average inter laboratory coefficients of variation (CVs) of, Patientennahe Diagnostik sichert die Überwachung der individuellen Hämostasekapazität von Patienten der Operativen und der Intensivmedizin. Die Thrombelastometrie bildet hierfür ein standardisiertes Spektrum von Messgrößen an. Die Herausforderung dieser schnellen diagnostischen Methode, die von „laborunerfahrenem“ Personal durchgeführt werden kann, bedeutet andererseits, dass ein besonderes Augenmerk auf valide Ergebnisse gelegt werden muss. Die externe Qualitätssicherung über Ringversuche stellt dafür ein probates Mittel dar, die für die Thrombelastometrie etabliert wurde. Die steigenden Teilnehmerzahlen und guten Bestehensquoten zeigen die hohe Relevanz dieser Thematik. Wir präsentieren hier eine Zusammenfassung der Ergebnisse und Erfahrungen aus vier konsekutiven Ringversuchen. Mit mittleren Interlabor-Variationskoeffizienten (VKs) von, GMS Zeitschrift zur Förderung der Qualitätssicherung in medizinischen Laboratorien; 7:Doc01
- Published
- 2016
- Full Text
- View/download PDF
8. Multiple Electrode Whole Blood Aggregometry, PFA-100, and In Vivo Bleeding Time for the Point-of-Care Assessment of Aspirin-Induced Platelet Dysfunction in the Preoperative Setting
- Author
-
Jámbor, Csilla, primary, von Pape, Klaus-Werner, additional, Spannagl, Michael, additional, Dietrich, Wulf, additional, Giebl, Andreas, additional, and Weisser, Heike, additional
- Published
- 2011
- Full Text
- View/download PDF
9. Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry
- Author
-
Kammerer, Tobias, Groene, Philipp, Sappel, Sophia R., Peterss, Sven, Sa, Paula A., Saller, Thomas, Giebl, Andreas, Scheiermann, Patrick, Hagl, Christian, Schaefer, Simon Thomas, Kammerer, Tobias, Groene, Philipp, Sappel, Sophia R., Peterss, Sven, Sa, Paula A., Saller, Thomas, Giebl, Andreas, Scheiermann, Patrick, Hagl, Christian, and Schaefer, Simon Thomas
- Abstract
Introduction: Tranexamic acid (TXA) is the standard medication to prevent or treat hyperfibrinolysis. However, prolonged inhibition of lysis (so-called fibrinolytic shutdown) correlates with increased mortality. A new viscoelastometric test enables bedside quantification of the antifibrinolytic activity of TXA using tissue plasminogen activator (TPA). Materials and Methods: Twenty-five cardiac surgery patients were included in this prospective observational study. In vivo, the viscoelastometric TPA test was used to determine lysis time (LT) and maximum lysis (ML) over 96 h after TXA bolus. Additionally, plasma concentrations of TXA and plasminogen activator inhibitor 1 (PAI-1) were measured. Moreover, dose effect curves from the blood of healthy volunteers were performed in vitro. Data are presented as median (25-75th percentile). Results: In vivo TXA plasma concentration correlated with LT (r = 0.55; p < 0.0001) and ML (r = 0.62; p < 0.0001) at all time points. Lysis was inhibited up to 96 h (LTTPA-test: baseline: 398 s [229-421 s] vs. at 96 h: 886 s [626-2,175 s]; p = 0.0013). After 24 h, some patients (n = 8) had normalized lysis, but others (n = 17) had strong lysis inhibition (ML p < 0.001). The high- and low-lysis groups differed regarding kidney function (cystatin C: 1.64 [1.42-2.02] vs. 1.28 [1.01-1.52] mg/L; p = 0.002) in a post hoc analysis. Of note, TXA plasma concentration after 24 h was significantly higher in patients with impaired renal function (9.70 [2.89-13.45] vs.1.41 [1.30-2.34] mu g/mL; p < 0.0001). In vitro, TXA concentrations of 10 mu g/mL effectively inhibited fibrinolysis in all blood samples. Conclusions: Determination of antifibrinolytic activity using the TPA test is feasible, and individual fibrinolytic capacity, e.g., in critically ill patients, can potentially be measured. This is of interest since TXA-induced lysis inhibition varies depending on kidney function.
10. Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry
- Author
-
Kammerer, Tobias, Groene, Philipp, Sappel, Sophia R., Peterss, Sven, Sa, Paula A., Saller, Thomas, Giebl, Andreas, Scheiermann, Patrick, Hagl, Christian, Schaefer, Simon Thomas, Kammerer, Tobias, Groene, Philipp, Sappel, Sophia R., Peterss, Sven, Sa, Paula A., Saller, Thomas, Giebl, Andreas, Scheiermann, Patrick, Hagl, Christian, and Schaefer, Simon Thomas
- Abstract
Introduction: Tranexamic acid (TXA) is the standard medication to prevent or treat hyperfibrinolysis. However, prolonged inhibition of lysis (so-called fibrinolytic shutdown) correlates with increased mortality. A new viscoelastometric test enables bedside quantification of the antifibrinolytic activity of TXA using tissue plasminogen activator (TPA). Materials and Methods: Twenty-five cardiac surgery patients were included in this prospective observational study. In vivo, the viscoelastometric TPA test was used to determine lysis time (LT) and maximum lysis (ML) over 96 h after TXA bolus. Additionally, plasma concentrations of TXA and plasminogen activator inhibitor 1 (PAI-1) were measured. Moreover, dose effect curves from the blood of healthy volunteers were performed in vitro. Data are presented as median (25-75th percentile). Results: In vivo TXA plasma concentration correlated with LT (r = 0.55; p < 0.0001) and ML (r = 0.62; p < 0.0001) at all time points. Lysis was inhibited up to 96 h (LTTPA-test: baseline: 398 s [229-421 s] vs. at 96 h: 886 s [626-2,175 s]; p = 0.0013). After 24 h, some patients (n = 8) had normalized lysis, but others (n = 17) had strong lysis inhibition (ML p < 0.001). The high- and low-lysis groups differed regarding kidney function (cystatin C: 1.64 [1.42-2.02] vs. 1.28 [1.01-1.52] mg/L; p = 0.002) in a post hoc analysis. Of note, TXA plasma concentration after 24 h was significantly higher in patients with impaired renal function (9.70 [2.89-13.45] vs.1.41 [1.30-2.34] mu g/mL; p < 0.0001). In vitro, TXA concentrations of 10 mu g/mL effectively inhibited fibrinolysis in all blood samples. Conclusions: Determination of antifibrinolytic activity using the TPA test is feasible, and individual fibrinolytic capacity, e.g., in critically ill patients, can potentially be measured. This is of interest since TXA-induced lysis inhibition varies depending on kidney function.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.